GRETA CAIN: Open Payments
NPI 1215363080 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$855 in 50 payments from 11 companies in 2025. Trend: 2023 $1,439 · 2024 $1,066 · 2025 $855
Food & beverage: $855
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $296 |
| Novo Nordisk Inc | 9 | $151 |
| Medtronic, Inc. | 1 | $83 |
| PFIZER INC. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Astellas Pharma US Inc | 2 | $41 |
| Exact Sciences Corporation | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 1 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Boston Scientific Corporation | 1 | $20 |
Products named: QULIPTA, UBRELVY, INCEPTIV, Rybelsus, NURTEC ODT, CAPLYTA, Ozempic, VRAYLAR.
Industry payments across MD — which companies pay providers there.
